| Identification | Back Directory | [Name]
l-aspartic acid-13c4,15n | [CAS]
202468-27-7 | [Synonyms]
15N,99％）| 1G
L-Aspartic-13C4, 15N Acid | [Molecular Formula]
HO213C13CH213CH(15NH2)13CO2H | [MDL Number]
MFCD00144566 | [MOL File]
202468-27-7.mol |
| Chemical Properties | Back Directory | [Melting point ]
>300 °C (dec.) (lit.) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Aqueous Base (Slightly) | [form ]
Solid | [color ]
White to Off-White | [Optical Rotation]
[α]25/D +25.0°, c = 2 in 5 M HCl | [InChI]
1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m0/s1/i1+1,2+1,3+1,4+1,5+1 | [InChIKey]
CKLJMWTZIZZHCS-NYTNKSBQSA-N | [SMILES]
[15NH2][13C@@H]([13CH2][13C](O)=O)[13C](O)=O | [CAS Number Unlabeled]
56-84-8 |
| Hazard Information | Back Directory | [Uses]
L-Aspartic acid-13C4,15N is the 13C-labeled and 15N-labeled L-Aspartic acid. L-Aspartic acid is is an amino acid, shown to be a suitable proagent for colon-specific agent deliverly. | [Definition]
ChEBI: Aspartic acid-13C4,15N is an aspartic acid derivative. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Hosoya K, et al. Blood-brain barrier produces significant efflux of L-aspartic acid but not D-aspartic acid: in vivo evidence using the brain efflux index method. J Neurochem. 1999 Sep;73(3):1206-11. DOI:10.1046/j.1471-4159.1999.0731206.x
[3] Leopold CS, et al. In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. J Pharmacokinet Biopharm. 1995 Aug;23(4):397-406. DOI:10.1007/BF02353640 |
|
| Company Name: |
Sigma-Aldrich
|
| Telephone: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
|